Homodimers but not monomers of Rituxan (chimeric anti-CD20) induce apoptosis in human B-lymphoma cells and synergize with a chemotherapeutic agent and an immunotoxin

Blood

Volumn 97, Issue 5, 2001, Pages 1392-1398

  Ghetie, Maria Ana ^a   Bright, Helen ^a   Vitetta, Ellen S ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DIMER; IMMUNOGLOBULIN G; RITUXIMAB;

APOPTOSIS; ARTICLE; B CELL LYMPHOMA; BURKITT LYMPHOMA; CELL GROWTH; CONTROLLED STUDY; DRUG EFFECT; DRUG HALF LIFE; DRUG POTENTIATION; DRUG SENSITIVITY; HUMAN; HUMAN CELL; IMMUNOGENICITY; PRIORITY JOURNAL; TUMOR CELL LINE;

EID: 0035282930     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V97.5.1392     Document Type: Article

References (31)

1. Homodimerization of tumor-reactive monoclonal antibodies markedly increases their ability to induce growth arrest or apoptosis of tumor cells
2. Monoclonal antibody homodimers: Enhanced antitumor activity in nude mice
3. Overview of the clinical development of rituximab: First monoclonal antibody approved for the treatment of lymphoma
4. Clinical applications of anti-CD20 antibodies
5. Rituximab chimeric anti-CD20 monocional antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program
6. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy
7. The antitumor effect of monoclonal anti-CD20 antibody (rnAb) therapy includes direct anti-proliferative activity and induction of apoptosis in CD20 positive non-Hodgkin's lymphoma (NHL) cell lines
8. Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs
9. Growth inhibition of CD20-positive B lymphoma cell lines by IDEC-C2B8 anti-CD20 monoclonal antibody
10. Rituximab induces caspase 3 mediated apoptosis of B-CLL cells despite rapid internationation of the CD20 protein
11. Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies
12. Anti-B4-blocked ricin synergizes with doxorubicin and etoposide on multidrug-resistant and drug-sensitive tumors
13. Depletion of B cells in vivo by a chimeric mouse human rnonoclonal antibody to CD20
14. Flow cytometry: Labeling of antibodies with fluorescein isothiocyanate (FITC)
15. Large scale preparation of immunotoxins constructed with the Fab fragment of IgG1 murine monoclonal antibodies and chemically deglycosylated ricin A chain
16. The GLP large scale preparation of immunotoxins containing deglycosylated ricin A chain and a hindered disulfide bond
17. Immunotoxins for the treatment of B-cell lymphomas
18. Clinical studies with deglycosylated ricin A-chain immunotoxins
19. The emerging role of ricin A-chain imrnunotoxins in leukemia and lymphoma
20. Cleavage of structural proteins during the assembly of the head of bacteriophage T4
21. Molecular cloning of the human B cell CD20 receptor predicts a hydrophobic protein with multiple transmembrane domains
22. CD20: A review
23. Fc-gamma receptor II (CD32) on malignant B cells influences modulation induced by anti-CD19 monoclonal antibody
24. The antitumor activity of an anti-CD22 immunotoxin in SCID mice with disseminated Daudi lymphoma is enhanced by either an anti-CD19 antibody or an anti-CD19 immunotoxin
25. Anti-CD19 inhibits the growth of human B-cell tumor lines in vitro and of Daudi cells in SCID mice by inducing cell cycle arrest
26. Monoclonal antibody-based therapies of leukemia and lymphoma
27. Antibodies as cytotoxic therapy
28. Humanized CD52 monoclonal antibody as first line treatment in chronic lymphocytic leukemia
29. Monoclonal antibody therapy of B cell lymphoma: Signaling activity on tumor cells appears more important than recruitment of effectors
30. Engineered humanized dimeric forms of IgG are more effective antibodies
31. Anti-CD19 antibodies inhibit the function of the P-gp pump in rnultidrug resistant B lymphoma cells